Literature DB >> 24964112

Seronegative Neuromyelitis Optica Spectrum--the challenges on disease definition and pathogenesis.

Douglas Kazutoshi Sato1, Dagoberto Callegaro2, Marco Aurélio Lana-Peixoto3, Ichiro Nakashima1, Kazuo Fujihara4.   

Abstract

Neuromyelitis optica spectrum disorders (NMOSD) are characterized by severe optic neuritis and/or longitudinally extensive transverse myelitis, and some brain lesions are also unique to NMOSD. Serum autoantibodies against aquaporin-4 (AQP4) are detected in most cases of NMOSD. However, some patients with NMOSD remain seronegative despite repetitive testing during attacks with highly sensitive cell-based assays. The differential diagnosis of NMOSD is not restricted to multiple sclerosis and it includes many diseases that can produce longitudinally extensive myelitis and/or optic neuritis. We review the clinical features, imaging, and laboratory findings that can be helpful on the diagnostic work-up, discuss the differences between AQP4 antibody positive and negative patients with NMOSD, including features of NMOSD with antibodies against myelin oligodendrocyte glycoprotein.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24964112     DOI: 10.1590/0004-282x20140032

Source DB:  PubMed          Journal:  Arq Neuropsiquiatr        ISSN: 0004-282X            Impact factor:   1.420


  8 in total

Review 1.  Myelopathy in sickle cell disease: a case-oriented review.

Authors:  Igor Vilela Brum; Guilherme Diogo Silva; Diego Sant'Ana Sodre; Felipe Melo Nogueira; Samira Luisa Dos Apostolos Pereira; Luiz Henrique Martins Castro
Journal:  Spinal Cord Ser Cases       Date:  2021-09-25

2.  Seronegative Neuromyelitis Optica Spectrum Disorder following Exposure to Hepatitis B Vaccination.

Authors:  Richard Heekin; Chetan Gandhy; Derrick Robertson
Journal:  Case Rep Neurol       Date:  2015-04-11

3.  The Urine Proteome Profile Is Different in Neuromyelitis Optica Compared to Multiple Sclerosis: A Clinical Proteome Study.

Authors:  Helle H Nielsen; Hans C Beck; Lars P Kristensen; Mark Burton; Tunde Csepany; Magdolna Simo; Peter Dioszeghy; Tobias Sejbaek; Manuela Grebing; Niels H H Heegaard; Zsolt Illes
Journal:  PLoS One       Date:  2015-10-13       Impact factor: 3.240

Review 4.  MOG-IgG-Associated Optic Neuritis, Encephalitis, and Myelitis: Lessons Learned From Neuromyelitis Optica Spectrum Disorder.

Authors:  Giordani Rodrigues Dos Passos; Luana Michelli Oliveira; Bruna Klein da Costa; Samira Luisa Apostolos-Pereira; Dagoberto Callegaro; Kazuo Fujihara; Douglas Kazutoshi Sato
Journal:  Front Neurol       Date:  2018-04-04       Impact factor: 4.003

5.  CSF-S100B Is a Potential Candidate Biomarker for Neuromyelitis Optica Spectrum Disorders.

Authors:  Yuzhen Wei; Haoxiao Chang; Xindi Li; Li Du; Wangshu Xu; Hengri Cong; Yajun Yao; Xinghu Zhang; Linlin Yin
Journal:  Biomed Res Int       Date:  2018-10-22       Impact factor: 3.411

6.  Neuromyelitis optica spectrum disorder: Patient experience and quality of life.

Authors:  Janine Beekman; Aysha Keisler; Omar Pedraza; Masayuki Haramura; Athos Gianella-Borradori; Eliezer Katz; John N Ratchford; Gerard Barron; Lawrence J Cook; Jacinta M Behne; Terrence F Blaschke; Terry J Smith; Michael R Yeaman
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2019-06-20

7.  Myelin Oligodendrocyte Glycoprotein (MOG)-IgG Associated Demyelinating Disease: Our Experience with this Distinct Syndrome.

Authors:  Shripad S Pujari; Rahul V Kulkarni; Dattatraya B Nadgir; Pawan K Ojha; Shashank Nagendra; Vikram Aglave; Rashmi D Nadgir; Hemant Sant; Nilesh Palasdeokar; Satish Nirhale; Sunil Bandishti
Journal:  Ann Indian Acad Neurol       Date:  2020-03-03       Impact factor: 1.383

Review 8.  Differential diagnosis of neuromyelitis optica spectrum disorders.

Authors:  Sung-Min Kim; Seong-Joon Kim; Haeng Jin Lee; Hiroshi Kuroda; Jacqueline Palace; Kazuo Fujihara
Journal:  Ther Adv Neurol Disord       Date:  2017-05-24       Impact factor: 6.570

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.